Journal of Internal Medicine 1992; **231**: 685–690

Author Index

Aalto-Setälä K, Koivisto U-M, Miettinen TA, Gylling H, Hesäniemi YA, Savolainen M, Pyörälä K, Ebeling T, Mononen I, Turtola H, Viikari J & Kontula K. Prevalence and geographical distribution of major LDL receptor gene rearrangements in Finland, 227
Ahlmark G, *see* Johansson S *et al.*, 511
Aho K, *see* Järvinen P *et al.*, 67
Albano O, *see* Palasciano G *et al.*, 123
Albers JJ, *see* Kastelein JJP *et al.*, 413
Almroth G, Eneström S, Hed J, Samuelsson I & Sjöström P. Autoantibodies to leucocyte antigens in hydralazine-associated nephritis, 37
Alván G. Genetic polymorphisms in drug metabolism, 571
Andersson OK, *see* Persson D *et al.*, 247
Aquilina J, *see* Pullicino PM *et al.*, 287
Arbin M. von, Britton M & de Faire U. Mortality and recurrences during eight years following stroke, 43
Arnold J, *see* Davis JW, 31
Arveiler D, *see* Nuttens MC *et al.*, 349
Ascari E, *see* Grignani G *et al.*, 81

Baldassare G, *see* Palasciano G *et al.*, 123
Balsløv JT, *see* Brahm M *et al.*, 339
Barnes PJ. New aspects of asthma, 453
Belfiore A, *see* Palasciano G *et al.*, 123
Bengtsson C, Blehmé G, Lapidus L, Lissner L & Lundgren H. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective study of women in Gothenburg, Sweden, 583
Bergström K, *see* Sylvén C *et al.*, 595
Bertoloni D, *see* Grignani G *et al.*, 81
Bestetti A, *see* Lomuscio A *et al.*, 73
Björkholm M. Aplastic anaemia: pathogenetic mechanisms and treatment with special reference to immunomodulation, 575
Björkholm M, *see* Östergren J *et al.*, 19
Blohmé G, *see* Bengtsson C *et al.*, 583
Böttiger LE. The post-mortem: its decline – and fall? 99
Boysen G, *see* Petersen P, 103
Brahm M, Brammer M, Balsløv JT, Brun C, Jørgensen HE, Gerstoft J, Lorenzen I & Thomsen ÅC. Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases, 339
Brammer M, *see* Brahm M *et al.*, 339
Breslow JL. The genetic basis of lipoprotein disorders: introduction and overview, 627
Brewer HB, *see* Fojo SS, 669
Britton M, *see* Arbin M von *et al.*, 43
Broomé U, *see* Eriksson LS *et al.*, 567
Brun C, *see* Brahm M *et al.*, 339

Cagnoni M, *see* Pignone A *et al.*, 617
Cambou JP, *see* Nuttens MC *et al.*, 349
Carlson JT, Hedner J, Fagerberg B, Ejnell H, Magnusson B & Fyhrquist F. Secondary polycythaemia associated with nocturnal apnoea – a relationship not mediated by erythropoietin? 381
Carlson K, Ljunghall S, Simonsson B & Smedmyr B. Serum osteocalcin concentrations in patients with multiple myeloma – correlation with disease stage and survival, 133
Carlsson B, *see* Palmblad J *et al.*, 363
Cernuschi M, *see* Franzetti F *et al.*, 437
Chapnick EK, *see* Gradon JD *et al.*, 317
Charles P. Calcium absorption and calcium bioavailability, 161
Chen J, *see* Sylvén C *see* 595
Chiaramello D, *see* Lomuscio A *et al.*, 73
Ching DWT & Leibowitz MR. Ketotifen – a therapeutic agent of eosinophilic fasciitis? 555
Chiti A, *see* Lomuscio A *et al.*, 73
Christensen KC, *see* Thorsen S *et al.*, 607
Cignarelli M, *see* Palasciano G *et al.*, 123
Craft JC, *see* Guay DRP, 295

Dal-Ré R. Elements of informed consent in clinical research with drugs: a survey of Spanish clinical investigators, 375
Dall'Aglio E, *see* Zavaroni I *et al.*, 235
Danielson BG, *see* Linde T *et al.*, 601
Danielsson Å, *see* Lindgren S *et al.*, 139
Davis JW & Arnold J. Time course of some effects of cigarette smoking on platelets, 31
de Faire U, *see* Arbin M von *et al.*, 43
de Wit R. AIDS-associated Kaposi's sarcoma and the mechanisms of interferon alpha's activity: a riddle within a puzzle, 321
Dedov II, *see* Shestakova MV *et al.*, 213
Dellborg M, *see* Markenvard J *et al.*, 433
Digy JP, *see* Sachon C *et al.*, 471
Drory Y, *see* Lev E *et al.*, 503
Druckner M, *see* Leibovici L *et al.*, 371
Dubois B, *see* Sachon C *et al.*, 471
Ducimetiere P, *see* Nuttens MC *et al.*, 349
Durrant SS, *see* Taha TH *et al.*, 543
Dyerberg J, *see* Gerdes LU *et al.*, 623

Ebeling T, *see* Aalto-Setälä K *et al.*, 227
Edvinsson L, *see* Ekkholm D *et al.*, 281
Egberg N, *see* Sylvén C *et al.*, 595
Eihk HG van, *see* Vreugdenhil G *et al.*, 547
Einarsson K, *see* Wedén M *et al.*, 561
Ejnell H, *see* Carlson JT *et al.*, 381
Ekeli T, *see* Otterstad JE *et al.*, 143, 493
Ekholm D, Edvinsson L, Ekman R & Thulin T. Plasma atrial natriuretic peptide (ANP) in relation to blood pressure in severe hypertension, 281
Ekman R, *see* Ekholm D *et al.*, 281
Eneström S, *see* Almroth G *et al.*, 37
Engström-Laurent A, *see* Nyberg A *et al.*, 485
Eriksson LS, Broomé U, Kalin M & Lindholm M. Hepatotoxicity due to repeated intake of low doses of paracetamol, 567
Eriksson P, *see* Holm S *et al.*, 115
Eriksson S, *see* Lindgren S *et al.*, 139
Erkelens DW, *see* Kastelein JJP *et al.*, 413

Ernst E, *see* Gerdes LU *et al.*, 623
Esposito R, *see* Franzetti F *et al.*, 437

Færgeman O, *see* Gerdes LU *et al.*, 623
Færk KK. Simultaneous occurrence of polymyalgia rheumatica in a married couple, 621
Fagerberg B, *see* Carlson JT *et al.*, 381
Fagrell B. Critical limb ischaemia: comments on a consensus document, 195
Fagrell B, *see* Östergren J *et al.*, 19
Farese RV Jr, Linton MF & Young SG. Apolipoprotein B gene mutations affecting cholesterol levels, 643
Fisman EZ, *see* Lev E *et al.*, 503
Fojo SS & Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II, 669
Franzetti F, Cernuschi M, Esposito R & Moroni M. *Pseudomonas* infections in patients with AIDS and AIDS-related complex, 437
Froeland, *see* Otterstad JE, 143, 493
Frohlich JJ, *see* Kastelein JJP *et al.*, 413
Fyhrquist F, *see* Carlson JT *et al.*, 381

Gahrton G. Multiple myeloma – a curable disease? 449
Gallicchio VS & Hughes NK. Effective modulation of the haematopoietic toxicity associated with zidovudine exposure to murine and human haematopoietic progenitor stem cells *in vitro* with lithium chloride, 219
Garanin G, *see* Wetzchewald D *et al.*, 303
Gasparini P, *see* Zavaroni I *et al.*, 235
Gerdes LU, Schmidt EB, Klausen IC, Kristensen SD, Ernst E, Færgeman O & Dyerberg J. Plasma concentration levels of apolipoprotein A-I, apolipoprotein B and lipoprotein(a) in Greenland Inuit (Eskimos), 623
Gerstoft J, *see* Brahm M *et al.*, 339
Gerstoft J, *see* Thorsen S *et al.*, 607
Gillnäs T, *see* Johansson S *et al.*, 511
Giorgino R, *see* Palasciano G *et al.*, 123
Gjørup T, Kelbæk H, Nielsen D, Kreiner S & Godtfredsen J. Interpretation of the electrocardiogram in suspected myocardial infarction: a randomized controlled study of the effect of a training programme to reduce interobserver variation, 407
Glaumann H, *see* Wedén M *et al.*, 561
Gobbi PG, *see* Grignani G *et al.*, 81
Godtfredsen J, *see* Gjørup T *et al.*, 407
Gonzalez A, *see* Miranda ME *et al.*, 77
Gradon JD, Chapnick EK & Sepkowitz DV. Zidovudine-induced hepatitis, 317
Grignani G, Gobbi PG, Piccolo G, Bertoloni D, Rossi A, Pieresca C, Legnani MC & Ascari E. Progressive necrotic myelopathy as a paraneoplastic syndrome: report of a case and some pathogenetic considerations, 81
Grimaldi A, *see* Sachon C *et al.*, 471
Grimfors G, *see* Palmblad J *et al.*, 363
Guay DRP & Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis, 295
Guerci A, Mainard D & Thiery D. Acute haematogenous osteomyelitis of the patella revealed by a pathological fracture in multiple myeloma, 87
Guldager B, Jelnes R, Jørgensen SJ, Nielsen SJ, Klaerke A, Mogensen K, Larsen KE, Reimer E, Holm J & Ottesen S. EDTA treatment of intermittent claudication – a double-blind, placebo-controlled study, 261
Gylling H, *see* Aalto-Setälä K *et al.*, 227
Gyntelberg F, *see* Hein HO *et al.*, 477

Hagerman I, *see* Sylvén C *et al.*, 595
Håkansson C, *see* Thorsen S *et al.*, 607
Hansen O, *see* Johansson S *et al.*, 511
Härkönen M, *see* Roine R *et al.*, 333
Heaney RP. Calcium in the prevention and treatment of osteoporosis, 169
Hed J, *see* Almroth G *et al.*, 37
Hedner J, *see* Carlson JT *et al.*, 381
Hedner T, *see* Persson D *et al.*, 247
Heikkonen E, *see* Roine R *et al.*, 333
Hein HO, Suadicani P & Gyntelberg F. Ischaemic heart disease incidence by social class and form of smoking: the Copenhagen Male Study – 17 years' follow-up, 477
Heliö T, Palotie A, Tötterman KJ, Ott J, Kauppinen-Mäkelin R & Tikkanen MJ. Lack of association between the apolipoprotein B gene 3′ hypervariable region alleles and coronary artery disease in Finnish patients with angiographically documented coronary artery disease, 49
Helve E, *see* Sane T *et al.*, 253
Hoffmann J, *see* Wetzchewald D *et al.*, 303
Holm A-C, *see* Mölgaard J *et al.*, 273
Holm J, *see* Guldager B *et al.*, 261
Holm S, Eriksson P, Karp K, Osterman G & Teien D. Quantitative assessment of aortic regurgitation by combined two-dimensional, continuous-wave and colour flow Doppler measurements, 115
Hughes NK, *see* Gallicchio VS, 219

Jacobsson S, *see* Johansson S *et al.*, 511
Jagenburg R, *see* Markenvard J *et al.*, 433
Janlert U. Unemployment and blood pressure in Swedish building labourers, 241
Järnmark M, *see* Palmblad J *et al.*, 363
Järvinen P, Kaprio J, Mäkitalo R, Koskenvuo M & Aho K. Systemic lupus erythematosus and related systemic diseases in a nationwide twin cohort: an increased prevalence of disease in MZ twins and concordance of disease features, 67
Jelnes R, *see* Guldager B *et al.*, 261
Johansson BW, *see* Johansson S *et al.*, 511
Johansson S, Nordin P, Wilhelmsen L, Tibblin G, Johansson BW, Hansen O, Ahlmark G, Jacobsson S, Michaeli E & Gillnäs T. Geographical variation and time trends in the attack rate of coronary heart disease in five Swedish cities, 511
Jørgensen HE, *see* Brahm M *et al.*, 339
Jørgensen SJ, *see* Guldager B *et al.*, 261
Jula A, Rönnemaa T, Tikkanen I & Karanko H. Responses of atrial natriuretic factor to long-term sodium restriction in mild to moderate hypertension, 521
Jürgensen HJ, *see* Thorsen S *et al.*, 607

Kaaja R, *see* Kangasniemi P, 551
Kalin M, *see* Eriksson LS *et al.*, 567
Kangasniemi P & Kaaja R. Ketoprofen and ergotamine in acute migraine, 551
Kaprio J, *see* Järvinen P *et al.*, 67
Karanko H, *see* Jula A *et al.*, 521
Karjalainen J, *see* Niskanen L *et al.*, 397
Karlberg B, *see* Persson D *et al.*, 247
Karlberg K-E, *see* Sylvén C *et al.*, 595
Karlsson A, *see* Thorsen S *et al.*, 607
Karp K, *see* Holm S *et al.*, 115

Kastelein JJP, Pritchard PH, Erkelens DW, Kuivenhoven JJ, Albers JJ & Frohlich JJ. Familial high-density-lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent, 413
Kauppinen R, *see* Mustajoki F *et al.*, 389
Kauppinen-Mäkelin R, *see* Heliö T *et al.*, 49
Kawada E, *see* Kurabayashi H *et al.*, 313
Kelbæk H, *see* Gjørup T *et al.*, 407
Kendall-Taylor P, *see* Perros P, 205
Kesäniemi YA, *see* Aalto-Setälä K *et al.*, 227
Klaerke A, *see* Guldager B *et al.*, 261
Klaus D, *see* Wetzchewald D *et al.*, 303
Klausen IC, *see* Gerdes LU *et al.*, 623
Knutsen KM, *see* Otterstad JE *et al.*, 493
Koistinen J, *see* Mustajoki F *et al.*, 389
Koivisto U-M, *see* Aalto-Setälä K *et al.*, 227
Kollind M, *see* Roll M *et al.*, 59
Konsiberger H, *see* Leibovici L *et al.*, 371
Kontula K, *see* Aalto-Setälä K *et al.*, 227
Koskenvuo M, *see* Järvinen P *et al.*, 67
Koskinen P, *see* Roine R *et al.*, 333
Kreiner S, *see* Gjørup T *et al.*, 407
Kristensen SD, *see* Gerdes LU *et al.*, 623
Kubota K, *see* Kurabayashi H *et al.*, 313
Kuivenhoven JJ, *see* Kastelein JJP *et al.*, 413
Kurabayashi H, Kubota K, Kawada E, Tamura K, Tamura J & Shirakura T. Complete cure of urinary and faecal incontinence after intravenous vitamin B_{12} therapy in a patient with postgastrectomy megaloblastic anaemia, 313

Lagerqvist B, *see* Waldenström A *et al.*, 327
Lannfelt L, *see* Mustajoki F *et al.*, 389
Lapidus L, *see* Bengtsson C *et al.*, 583
Larsen KE, *see* Guldager B *et al.*, 261
Larsson K, *see* Lindh E *et al.*, 403
Lassen J, *see* Saebø A, 531, 537
Lassvik C, *see* Mölgaard J *et al.*, 273
Laurberg P, *see* Vestergaard H, 13
Lavö R, *see* Lindh E *et al.*, 403
Laws A & Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations, 25
Lecerf JM, *see* Nuttens MC *et al.*, 349
Legnani MC, *see* Grignani G *et al.*, 81
Leibovici L, Konsiberger H, Pitlik SD, Samra Z & Druckner M. Patients at risk for inappropriate antibiotic treatment of bacteraemia, 371
Leibowitz MR, *see* Ching DWT, 555
Lerner R, *see* Palmblad J *et al.*, 363
Lev E, Tordjman K, Pines A, Fisman EZ, Drory Y & Stern N. Neurocirculatory asthenia revisited: elevated arterial pressure at presentation is a marker for subsequent hypertension, 503
Lilius L, *see* Mustajoki F *et al.*, 389
Lind L, Wengle B, Lithell H & Ljunghall S. Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (Alphacalcidol), 427
Linde T, Sandhagen B, Danielson BG & Wikström B. Impaired erythrocyte fluidity during treatment of renal anaemia with erythropoietin, 601
Lindh E, Ljunghall S, Larsson K & Lavö R. Screening for antibodies against gliadin in patients with osteoporosis, 403
Lindemans J, *see* Vreugdenhil G *et al.*, 547
Lindgren S, Danielsson Å, Olsson R, Prytz H & Eriksson S. Prednimustin treatment in primary biliary cirrhosis: a preliminary study, 139
Lindholm M, *see* Eriksson LS *et al.*, 567
Lindqvist U, *see* Nyberg A *et al.*, 485
Linton MF, *see* Farese RV Jr *et al.*, 643
Lissner L, *see* Bengtsson C *et al.*, 583
Lithell H, *see* Lind L *et al.*, 427
Ljunghall S, *see* Carlson K *et al.*, 133
Ljunghall S, *see* Lind L *et al.*, 427
Ljunghall S, *see* Lindh E *et al.*, 403
Ljungman P, *see* Palmblad J *et al.*, 363
Lohr E, *see* Wetzchewald D *et al.*, 303
Lombardi A, *see* Pignone A *et al.*, 617
Lomuscio A, Bestetti A, Vergani D, Chiaramello D, Chiti A, Ruffini L, Pozzoni L & Tarolo GL. Radionuclide assessment of left ventricular function in patients with myocardial infarction and diabetes mellitus, 73
Lönnqvist B, *see* Palmblad J *et al.*, 363
Lorenzen I, *see* Brahm M *et al.*, 339
Lundgren H, *see* Bengtsson C *et al.*, 583
Luurila OJ, *see* Roine R *et al.*, 333
Luurila OJ. The sauna and the heart, 319
Luzzatto L. Gene transfer and gene therapy, 3

Magnusson B, *see* Carlson JT *et al.*, 381
Mahley RW, *see* Rall SC Jr, 653
Mainard D, *see* Guerci A *et al.*, 87
Mäkitalo R, *see* Järvinen P *et al.*, 67
Malinow MR, *see* Mölgaard J *et al.*, 273
Markenvard J, Dellborg M, Jagenburg R & Swedberg K. The predictive value of CKMB mass concentration in unstable angina pectoris: preliminary report, 433
Matkovic V. Calcium and peak bone mass, 151
Matucci-Cerinic M, *see* Pignone A *et al.*, 617
Mazeika PK, *see* Taha TH *et al.*, 543
Mazza S, *see* Zavaroni I *et al.*, 235
Merino JL, *see* Miranda ME *et al.*, 77
Michaeli E, *see* Johansson S *et al.*, 511
Michelsen S, *see* Otterstad JE *et al.*, 143
Miettinen TA, *see* Aalto-Setälä K *et al.*, 227
Miller HJ, *see* Tanus T, 445
Miranda ME, Gonzalez A, Merino JL & Puig JG. Intrafamilial outbreak of Mediterranean spotted fever, 77
Miyawaki S, *see* Murakami H *et al.*, 129
Mogensen K, *see* Guldager B *et al.*, 261
Molčányiová A, *see* Tkáč I *et al.*, 109
Mölgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B & Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication, 273
Mononen I, *see* Aalto-Setálä K *et al.*, 227
Morfini M, *see* Pignone A *et al.*, 617
Morini M, *see* Franzetti F *et al.*, 437
Mosekilde L. Osteoporosis and calcium, 145
Mukkin NA, *see* Shestakova MV *et al.*, 213
Murakami H, Nemoto K, Miyawaki WS, Shinonome S, Nogiwa E, Shimano S, Sato S, Omine M, Naruse T & Tsuchiya J. Ten-year survivors with multiple myeloma, 129
Mustajoki F, Kauppinen R, Lannfelt L, Lilius L & Koistinen J. Frequency of low erythrocyte porphobilinogen deaminase activity in Finland, 389

Naruse T, *see* Murakami H *et al.*, 129
Nemoto K, *see* Murakami H *et al.*, 129

Nielsen D, *see* Gjørup T *et al.*, 407
Nielsen JO, *see* Thorsen S *et al.*, 607
Nielsen SJ, *see* Guldager B *et al.*, 261
Nihoyannopoulos P, *see* Taha TH *et al.*, 543
Niskanen L, Siitonen O, Karjalainen J & Uusitupa M. Hyperglycaemic symptoms before diagnosis of non-insulin-dependent (type 2) diabetes mellitus in relation to 5-year outcome, 397
Nogiwa E, *see* Murakami H *et al.*, 129
Nordin P, *see* Johansson S *et al.*, 511
Nordrehaug JE, Omsjø IH & Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure, 589
Norkrans G, *see* Thorsen S *et al.*, 607
Nuttens MC, Romon M, Ruidavets JB, Arveiler D, Ducimetiere P, Lecerf JM, Richard JL, Cambou JP, Simon C & Salomez JL. Relationship between smoking and diet: the MONICA-France project, 349
Nyberg A, Lindqvist U & Engström-Laurent A. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: relation to clinical symptoms, liver histopathology and outcome, 485
Nyström-Rosander C, *see* Palmblad J *et al.*, 363

Oakley CM, *see* Taha TH *et al.*, 543
Öberg G, *see* Palmblad J *et al.*, 363
Odeh M. The role of zinc in acquired immunodeficiency syndrome, 463
Olsson AG, *see* Mölgaard J *et al.*, 273
Olsson R, *see* Lindgren S *et al.*, 139
Omine M, *see* Murakami H *et al.*, 129
Omsjø IH, *see* Nordrehaug JE *et al.*, 589
Östergren J, Fagrell B & Björkholm M. Hyperleukocytic effects on skin capillary circulation in patients with leukaemia, 19
Osterman G, *see* Holm S *et al.*, 115
Ott J, *see* Heliö T *et al.*, 49
Otterstad JE, Froeland G, Michelsen S & Ekeli T. Are there differences in the blood-pressure-lowering effect of atenolol vs. hydrochlorothiazide + amiloride (Moduretic) when assessed by standard clinic recordings vs. 24-h ambulatory monitoring? 143
Otterstad JE, Froeland G, Wasenius Soeyland AK, Knutsen KM & Ekeli T. Changes in left ventricular dimensions and systolic function in 100 mildly hypertensive men during one year's treatment with atenolol vs. hydrochlorothiazide and amiloride (Moduretic): a double-blind, randomized study, 493
Ottesen S, *see* Guldager B *et al.*, 261

Palasciano G, Portincasa P, Belfiore A, Baldassarre G, Cignarelli M, Paternostro A, Albano O & Giorgino R. Gallbladder volume and emptying in diabetics: the role of neuropathy and obesity, 123
Palmblad J, Lönnqvist B, Carlsson B, Grimfors G, Järnmark M, Lerner R, Ljungman P, Nyström-Rosander C, Petrini B & Öberg G. Oral ketoconazole prophylaxis for *Candida* infections during induction therapy for acute leukaemia in adults: more bacteraemias, 363
Palotie A, *see* Heliö T *et al.*, 49
Passeri M, *see* Zavaroni I *et al.*, 235
Paternostro A, *see* Palasciano G *et al.*, 123
Pedersen C, *see* Thorsen S *et al.*, 607
Pehrson PO, *see* Thorsen S *et al.*, 607
Perros P & Kendall-Taylor P. Pathogenic mechanisms in thyroid-associated ophthalmopathy, 205
Persson D, Andersson OK, Wysocki M, Hedner T & Karlberg B. Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria, 247
Petersen CS, *see* Thorsen S *et al.*, 607
Petersen P & Boysen G. Ischaemic stroke – prevention and treatment, 103
Petrini B, *see* Palmblad J *et al.*, 363
Piccolo G, *see* Grignani G *et al.*, 81
Piedmonte MR, *see* Pullicino PM *et al.*, 287
Pieresca C, *see* Grignani G *et al.*, 81
Pignone A, Matucci-Cerinic M, Morfini M, Lombardi A, Rossi Ferrini PL & Cagnoni M. Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cytophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis, 617
Pillon B, *see* Sachon C *et al.*, 471
Pines A, *see* Lev E *et al.*, 503
Pitlik SD, *see* Leibovici L *et al.*, 371
Portincasa P, *see* Palasciano G *et al.*, 123
Pozzoni L, *see* Lomuscio A *et al.*, 73
Pritchard PH, *see* Kastelein JJP *et al.*, 413
Prytz H, *see* Lindgren S *et al.*, 139
Puig JG, *see* Miranda ME *et al.*, 77
Pullicino PM, Xuereb M, Aqulina J & Piedmonte MR. Stroke following acute myocardial infarction in diabetics, 287
Pyörälä K, *see* Aalto-Setälä J *et al.*, 227

Rall SC Jr & Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders, 653
Reaven GM, *see* Laws A, 25
Reaven GM, *see* Zavaroni I *et al.*, 235
Reimer E, *see* Guldager B *et al.*, 261
Richard JL, *see* Nuttens MC *et al.*, 349
Riis P. Generatio- and topocentricity – widespread contemporary attitudes to clinical research, 1
Robins SJ, *see* Rubins HB, 421
Roine R, Luurila OJ, Soukas A, Heikkonen E, Koskinen P, Ylikahri R, Toivonen L, Härkönen M & Salaspuro M. Alcohol and sauna bathing: effects on cardiac rhythm, blood pressure and serum electrolyte and cortisol concentrations, 333
Roll M, Kollind M & Theorell T. Five-year follow-up of young adults visiting an emergency unit because of atypical chest pain, 59
Romon M, *see* Nuttens MC *et al.*, 349
Rönnemaa T, *see* Jula A *et al.*, 521
Ronquist G, *see* Waldenström A *et al.*, 327
Rosengren A, Wilhelmsen L & Wedel H. Coronary heart disease, cancer and mortality in male middle-aged light smokers, 357
Rossi A, *see* Grignani G *et al.*, 81
Rossi Ferrini PL, *see* Pignone A *et al.*, 617
Rubins HB & Robins SJ. Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein cholesterol concentrations, 421
Ruffini L, *see* Lomuscio A *et al.*, 73
Ruidavets JB, *see* Nuttens MC *et al.*, 349
Rydén L. Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance, 7

Sachon C, Grimaldi A, Digy JP, Pillon B, Dubois B & Thervet F. Cognitive function, insulin-dependent diabetes and hypoglycaemia, 471
Saebø A & Lassen J. Acute and chronic liver disease associated with *Yersinia enterocolitica* infection: a Norwegian 10-year follow-up study of 458 hospitalized patients, 531
Saebø A & Lassen J. Acute and chronic pancreatic disease associated with *Yersinia enterocolitica* infection: a Norwegian 10-year follow-up study of 458 hospitalized patients, 537
Salaspuro M, *see* Roine R *et al.*, 333
Salomez JL, *see* Nuttens MC *et al.*, 349
Samra Z, *see* Leibovici L *et al.*, 371
Samuelsson I, *see* Almroth G *et al.*, 37
Sandhagen B, *see* Linde T *et al.*, 601
Sandstrom E, *see* Thorsen S *et al.*, 607
Sane T, Helve E, Yki-Järvinen H & Taskinen M-R. One-year response to evening insulin therapy in non-insulin-dependent diabetes, 253
Sato S, *see* Murakami H *et al.*, 129
Savolainen M, *see* Aalto-Setälä K *et al.*, 227
Scandinavian Isoprinosine Study Group, *see* Thorsen S *et al.*, 607
Scanu AM. Genetic basis and pathophysiological implications of high plasma Lp(a) levels, 679
Schaafsma G. The scientific basis of recommended dietary allowances for calcium, 187
Schmidt EB, *see* Gerdes LU *et al.*, 623
Sepkowitz DV, *see* Gradon JD *et al.*, 317
Shestakova MV, Mukkin NA, Dedov II, Titov VN & Warshavsky VA. Protein-loading test, urinary albumin excretion and renal morphology in diagnosis of subclinical diabetic nephropathy, 213
Shimano S, *see* Murakami H *et al.*, 129
Shinonome S, *see* Murakami H *et al.*, 129
Shirakura T, *see* Kurabayashi H *et al.*, 313
Siitonen O, *see* Niskanen L *et al.*, 397
Simon C, *see* Nuttens MC *et al.*, 349
Simonsson B, *see* Carlson K *et al.*, 133
Sjöström P, *see* Almroth G *et al.*, 37
Smedmyr B, *see* Carlson K *et al.*, 133
Sorva A, Valvanne J & Tilvis RS. Serum ionized calcium and the prevalence of primary hyperparathyroidism in age cohorts of 75, 80 and 85 years, 309
Soutar AK. Familial hypercholesterolaemia and LDL receptor mutations, 633
Stern N, *see* Lev E *et al.*, 503
Suadicani P, *see* Hein HO *et al.*, 477
Suokas A, *see* Roine R *et al.*, 333
Swaak AJG, *see* Vreugdenhil G *et al.*, 547
Swedberg K, *see* Markenvard J *et al.*, 433
Sylvén C, Karlberg K-E, Chen J, Hagerman I, Egberg N & Bergström K. Enhanced platelet function in acute myocardial infarction is attenuated by streptokinase treatment, 595

Taha TH, Durrant SS, Mazeika PK, Nihoyannopoulos P & Oakley CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis, 543
Takáč M, *see* Tkáč I *et al.*, 109
Tall AR. Metabolic and genetic control of HDL cholesterol levels, 661
Tamura J, *see* Kurabayashi H *et al.*, 313
Tamura K, *see* Kurabayashi H *et al.*, 313
Tanus T & Miller HJ. POEMS syndrome presenting with cardiomegaly and cardiomyopathy, 445
Tarolo GL, *see* Lomuscio A *et al.*, 73
Taskinen M-R, *see* Sane T *et al.*, 253
Teien D, *see* Holm S *et al.*, 115
Theorell T, *see* Roll M *et al.*, 59
Thervet F, *see* Sachon C *et al.*, 471
Thiery D, *see* Guerci A *et al.*, 87
Thomsen ÅC, *see* Brahm M *et al.*, 339
Thorsen S, Pedersen C, Sandstrom E, Petersen CS, Norkrans G, Gerstoft J, Karlsson A, Christensen KC, Håkansson C, Pehrson PO, Nielsen JO, Jürgensen HJ & Scandinavian Isoprinosine Study Group. One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection, 607
Thulin T, *see* Ekholm D *et al.*, 281
Tibblin G, *see* Johansson S *et al.*, 511
Tikkanen I, *see* Jula A *et al.*, 521
Tikkanen MJ, *see* Heliö T *et al.*, 49
Tilvis RS, *see* Sorva A *et al.*, 309
Titov VN, *see* Shestakova MV *et al.*, 213
Tkáč I, Molčányiova A, Tkáčová R & Takač M. Levels of cardiovascular risk factors in Type 2 diabetes mellitus are dependent on the stage of proteinuria, 109
Tkáčová R, *see* Tkáč I *et al.*, 109
Toivonen L, *see* Roine R *et al.*, 333
Tordjman K, *see* Lev E *et al.*, 503
Toss G. Effect of calcium intake vs. other life-style factors on bone mass, 181
Tötterman KJ, *see* Heliö T *et al.*, 49
Tsuchiya J, *see* Murakami H *et al.*, 129
Turtola H, *see* Aalto-Setälä K *et al.*, 227
Tytgat GNJ. *Heliobacter pylori* infection and duodenal ulcer disease, 199

Upson B, *see* Mölgaard J *et al.*, 273
Uusitupa M, *see* Niskanen L *et al.*, 397

Valvanne J, *see* Sorva A *et al.*, 309
Vergani D, *see* Lomuscio A *et al.*, 73
Vestergaard H & Laurberg P. Radioiodine treatment of recurrent hyperthyroidism in patients previously treated for Graves' disease by subtotal thyroidectomy, 13
Viikari J, *see* Aalto-Setälä K *et al.*, 227
Vollset SE, *see* Nordrehaug JE *et al.*, 589
Vreugdenhil G, Lindemans J, Eijk HG van & Swaak AJG. Elevated serum transcobalamin levels in anaemia of rheumatoid arthritis: correlation with disease activity but not with serum tumour necrosis factor alpha and interleukin 6, 547

Waldenström A, Ronquist G & Lagerqvist B. Angina pectoris patients with normal coronary angiograms but abnormal thallium perfusion scan exhibit low myocardial and skeletal muscle energy charge, 327
Warshavsky VA, *see* Shestakova MV *et al.*, 213
Wasenius Soeyland AK, *see* Otterstad JE *et al.*, 493
Wedel H, *see* Rosengren A *et al.*, 357
Wedén M, Glaumann H & Einarsson K. Protracted cholestasis probably induced by oral contraceptive, 561
Wengle B, *see* Lind L *et al.*, 427
Wetzchewald D, Klaus D, Garanin G, Lohr E & Hoffmann J. Regression of left ventricular hypertrophy during long-term antihypertensive treatment – a comparison between felodipine and the combination of felodipine and metoprolol, 303
Wikström B, *see* Linde T *et al.*, 601
Wilhelmsen L, *see* Johansson S *et al.*, 511

Wilhelmsen L, *see* Rosengren A *et al.*, 357
Wysocki M, *see* Persson D *et al.*, 247

Xuereb M, *see* Pullicino PM *et al.*, 287

Yki-Järvinen H, *see* Sane T *et al.*, 253
Ylikahri R, *see* Roine R *et al.*, 333
Young SG, *see* Farese RV Jr *et al.*, 643

Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M & Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure, 235

Journal of Internal Medicine 1992; 231: 691–695

Subject Index

Acute intermittent porphyria
  erythrocyte porphobilinogen deaminase activity in, 389
Adenine nucleotides
  in angina pectoris, 327
Aetiology
  of polymyalgia rheumatica, 621
Ageing
  and hyperparathyroidism, 309
Agranulocytosis
  GM-CSF therapy for, 269
AIDS
  zidovudine-induced hepatitis in, 317
  -associated Kaposi's sarcoma, 321
  Pseudomonas infections in, 437
  role of zinc in, 463
Alcohol
  and calcium intake, 181
  and sauna bathing, 333
Amiloride
  as antihypertensive therapy, 143
  effect on left ventricular dimensions and systolic function, 493
Ampicillin
  in treatment of chronic bronchitis, 295
Anaemia
  of rheumatoid arthritis, transcobalamin levels in, 547
Angina pectoris
  efficacy of epanolol vs. metoprolol, 7
  and myocardial and skeletal energy charge, 327
  predictive value of CKMB mass concentration in, 433
Antibiotics
  inappropriate treatment of bacteraemia, 371
Antihypertensive drugs
  diabetes incidence in relation to use of, 583
Anxiety
  and atypical chest pain, 59
Aortic regurgitation
  quantitative assessment of, 115
Aplastic anaemia
  pathogenetic mechanisms and treatment, 575
Apolipoprotein
  B, and coronary artery disease, 49
  in Greenland Inuit (Eskimos), 623
  B gene mutations, effect on cholesterol levels, 643
  E, role in lipoprotein disorders, 653
  C-II, hypertriglyceridaemia due to genetic defects in, 669
Aspirin
  for prevention of stroke and growth of vegetations, 543
Asthma
  new aspects of, 453
Atenolol
  as antihypertensive therapy, 143
  effect on left ventricular dimensions and systolic function, 493
Atherosclerosis
  chelation therapy in, 261
Atrial natriuretic factor
  response to long-term sodium restriction, 521
Atrial natriuretic peptide
  and severe hypertension, 281
Autoantibodies
  to leucocyte antigens, 37

Bacteraemia
  effect of oral ketoconazole prophylaxis in leukaemia, 363
  inappropriate antibiotic treatment, 371
Benazepril
  effect in symptomatic mild heart failure, 589
Beta-blockers
  in treatment of angina pectoris, 7
Blood pressure
  and unemployment, 241
Bone loss
  and calcium, 169
Bone-marrow transplantation
  and aplastic anaemia, 575

Calcium
  and osteoporosis, 145, 169
  and peak bone mass, 151
  absorption and bioavailability, 161
  dietary, 161
  supplements, 161
  deficiency, 169
  intake, vs. other life-style factors, 181
  and prevention of osteoporosis, 187
  recommended dietary allowances, 187
  antagonism in essential hypertension, 247
  and prevalence of primary hyperparathyroidism, 309
  and cardiovascular risk factors in hyperparathyroidism, 427
Cancer
  coronary heart disease and mortality in smokers, 357
Cardiomyopathy
  POEMS syndrome presenting with, 445
Cardiovascular disease
  and plasma lipoprotein(a) levels, 623
Cardiovascular risk factors
  in type 2 diabetes mellitus, 109
  and calcium in hyperparathyroidism, 427
Chelation therapy
  in intermittent claudication, 261
Chest pain
  atypical, admissions due to, 59
Cholestasis
  intrahepatic, induction by oral contraceptive, 561
Cholesterol
  levels, effect of apolipoprotein B gene mutations, 643
Chronic bronchitis
  clarithromycin and ampicillin in treatment of, 295
Clarithromycin
  in treatment of chronic bronchitis, 295
Clinical investigators
  survey of, 375
Clinical trials
  elements of informed consent in, 375
Coeliac disease
  and osteoporosis, 403

Cognitive function
  insulin-dependent diabetes and hypoglycaemia, 471
Corneal opacities
  HDL-cholesterol deficiency causing, 413
Coronary heart disease
  and apolipoprotein B gene, 49
  cancer and mortality in smokers, 357
  geographical variation and time trends in, 511
Creatine kinase
  MB isoenzyme mass concentration in angina pectoris, 433
Creatinine
  levels, changes during glomerulonephritis, 339
Critical limb ischaemia
  comments on a consensus document, 195
Cyclophosphamide
  for correction of factor VIII deficiency, 617

Depression
  and atypical chest pain, 59
Diabetes mellitus
  assessment of left ventricular function in, 73
  cardiovascular risk factors in, 109
  gallbladder volume and emptying in, 123
  response to evening insulin therapy in, 253
  stroke following myocardial infarction in, 287
  hyperglycaemic symptoms before diagnosis of, 397
  cognitive function and hypoglycaemia, 471
  and *Yersinia enterocolitica* infection, 537
  and use of antihypertensive drugs, 583
Diet
  and smoking habits, 349
Diuretics
  in symptomatic mild heart failure, 589
Doppler echocardiography
  assessment of aortic regurgitation, 115
Drug metabolism
  genetic polymorphisms in, 571
Duodenal ulcer disease
  and *Heliobacter pylori* infection, 199
Dyslipidaemia
  hyperinsulinaemia and hypertension, 235

Elastase
  effect of streptokinase treatment, 595
Electrocardiography
  interpretation in suspected myocardial infarction, 407
Emergency unit
  admissions due to atypical chest pain, 59
Eosinophilic fasciitis
  ketotifen in therapy of, 555
Epanolol
  efficacy in angina pectoris, 7
Epidemiology
  of Mediterranean spotted fever, 77
Ergotamine
  and ketoprofen in acute migraine, 551
Erythrocyte fluidity
  during erythropoietin treatment, 601
Erythropoietin
  and obstructive sleep apnoea, 381
  treatment of renal anaemia with, 601

Factor VIII
  deficiency in rheumatoid arthritis, 617
  suppression of autoantibodies to, 617
Faecal incontinence
  intravenous vitamin B_{12} therapy for, 313
Familial hypercholesterolaemia
  major LDL receptor gene rearrangements in, 227
  and LDL receptor mutations, 633
Felodipine
  and reduction of left ventricular hypertrophy, 303
Fibrinogen
  effect of streptokinase treatment, 595
Fish eye disease
  HDL-cholesterol deficiency causing, 413
Folic acid
  supplementation in hyperhomocyst(e)inaemic patients, 273
Fungal infections
  in leukaemia, oral ketoconazole prophylaxis, 363

Gall bladder
  volume and emptying in diabetics, 123
Gemfibrozil
  effect of reduction of plasma triglycerides with, 421
Gene transfer
  and gene therapy, 3
Genetic polymorphisms
  in drug metabolism, 571
  and cholesterol levels, 643, 661
Geographical variation
  in incidence of coronary heart disease, 511
Gliadin antibodies
  in patients with osteoporosis, 403
Glomerulonephritis
  hydralazine-associated, 37
  prognosis in, 339
GM-CSF therapy
  for drug-induced agranulocytosis, 269
Graves' disease
  radioiodine treatment in patients with, 13

Haematogenous osteomyelitis
  and multiple myeloma, 87
Haematopoietic toxicity
  associated with zidovudine therapy, 219
Haematopoietins
  and aplastic anaemia, 575
HDL-cholesterol
  and insulin resistance, 25
  deficiency causing corneal opacities, 413
  effect of reduction of plasma triglycerides on, 421
  levels, metabolic and genetic control of, 661
Heart
  effects of alcohol and sauna bathing on, 333
Heart failure
  effect of benazepril and hydrochlorothiazide on, 589
Heat stress
  and alcohol, effect on heart, 333
Helicobacter pylori
  infection, and duodenal ulcer disease, 199
Hepatitis
  induced by zidovudine, 317
Hepatotoxicity
  due to repeated intake of paracetamol, 567

HIV infection
and therapy for *Pseudomonas* infections, 437
safety and efficacy of isoprinosine in, 607
Hyaluronan
in primary biliary cirrhosis, 485
Hydralazine
-associated glomerulonephritis, 37
Hydrochlorothiazide
as antihypertensive therapy, 143
effect on left ventricular dimensions and systolic function, 493
effect in symptomatic mild heart failure, 589
Hyperglycaemia
before diagnosis of diabetes mellitus, 397
Hyperhomocyst(e)inaemia
risk factor for intermittent claudication, 273
Hyperinsulinaemia
prevalence in hypertensive patients, 235
and use of antihypertensive drugs, 583
Hyperleukocytic syndrome
in leukaemia patients, 19
Hyperlipoproteinaemia
apolipoprotein E genetic variants in, 653
Hyperparathyroidism
calcium and cardiovascular risk factors in, 427
Hypertension
therapy with atenolol vs. hydrochlorothiazide + amiloride, 143
prevalence of hyperinsulinaemia in, 235
calcium antagonism in, 247
and plasma atrial natriuretic peptide, 281
regression of left ventricular hypertrophy during long-term treatment of, 303
calcium and cardiovascular risk factors, 427
effect of atenolol vs. hydrochlorothiazide and amiloride, 493
neurocirculatory asthenia as a marker for, 503
response of atrial natriuretic factor in, 521
and erythropoietin treatment, 601
Hyperthyroidism
radioiodine treatment of, 13
Hypertriglyceridaemia
due to genetic defects, 669
Hypoglycaemia
cognitive function and diabetes, 471

Immunomodulation
and aplastic anaemia, 575
Infective endocarditis
aspirin for prevention of stroke in, 543
Informed consent
elements of, in clinical research with drugs, 375
Insulin
resistance and fasting plasma HDL-cholesterol, 25
evening therapy, one-year response to, 253
Interferon alpha
and AIDS-associated Kaposi's sarcoma, 321
Interleukin 6
in anaemia of rheumatoid arthritis, 547
Intermittent claudication
EDTA treatment of, 261
hyperhomocyst(e)inaemia as risk factor for, 273
Ischaemic heart disease
social class and smoking, 477
Ischaemic stroke
prevention and treatment, 103

Isoprinosine
safety and efficacy for HIV infection, 607

Kaposi's sarcoma
and interferon alpha activity, 321
Ketoconazole
prophylaxis for *Candida* infections in leukaemia, 363
Ketoprofen
and ergotamine in acute migraine, 551
Ketotifen
in therapy of eosinophilic fasciitis, 555

LDL receptor
gene prevalence and geographical distribution of, 227
mutations and familial hypercholesterolaemia, 633
Lecithin: cholesterol acyltransferase
deficiency, causing corneal opacities, 413
Left ventricular dimensions
effect of atenolol vs. hydrochlorothiazide and amiloride, 493
Left ventricular function
radionuclide assessment of, 73
Left ventricular hypertrophy
regression during antihypertensive treatment, 303
and long-term sodium restriction, 521
Leucocyte antigens
in hydralazine-associated nephritis, 37
Leukaemia
hyperleukocytic syndrome in, 19
oral ketoconazole prophylaxis for *Candida* infections during, 363
Lipoprotein disorders
role of apolipoprotein E genetic variants in, 653
Lipoprotein lipase
hypertriglyceridaemia due to genetic defects in, 669
Lipoprotein(a)
genetic basis and pathophysiological implications of high levels, 679
Lithium
effect on zidovudine toxicity, 219
Liver disease
serum hyaluronan and aminoterminal propeptide in, 485
associated with *Yersinia enterocolitica* infection, 531

Mediterranean spotted fever
intrafamilial outbreak of, 77
Metoprolol
efficacy in angina pectoris, 7
and reduction of left ventricular hypertrophy, 303
Microalbuminuria
effect of calcium antagonism in essential hypertension, 247
Migraine
ketoprofen and ergotamine in, 551
Moduretic
effect on left ventricular dimensions and systolic function, 493
Mortality
and recurrences following stroke, 43
coronary heart disease and cancer in smokers, 357
and coronary heart disease in Sweden, 511
Multiple myeloma
acute haematogenous osteomyelitis and, 87
prognostic factors associated with survival, 129
serum osteocalcin concentrations in, 133
as a curable disease, 449

Myocardial infarction
assessment of left ventricular function in, 73
followed by stroke in diabetics, 287
interpretation of electrocardiogram in suspected, 407
enhanced platelet function in, 595
Myocardial metabolism
in angina pectoris, 327

Necrotic myelopathy
as a paraneoplastic syndrome, 81
Nephropathy
diagnosis in diabetes mellitus, 213
Neurocirculatory asthenia
as a marker for subsequent hypertension, 503
Neuropathy
and gallbladder volume in diabetics, 123
Nicotine
effect on platelet function, 31

Obesity
and gallbladder volume in diabetics, 123
diabetes and antihypertensive drugs, 583
Ophthalmopathy
thyroid-associated, pathogenetic mechanisms in, 205
Oral contraceptive
induction of protracted cholestasis, 561
Osteocalcin
serum levels in multiple myeloma, 133
Osteoporosis
and calcium, 145, 169
and peak bone mass, 151
and coeliac disease, 403
screening for gliadin antibodies in, 403

Pancreatitis
associated with *Yersinia enterocolitica* infection, 537
Paracetamol
hepatotoxicity due to repeated intake of, 567
Paraneoplastic syndrome
progressive necrotic myelopathy as a, 81
Pathogenetic mechanisms
in thyroid-associated ophthalmopathy, 205
Peak bone mass
and calcium, 151
Physical activity
and calcium intake, 181
ischaemic heart disease and smoking, 477
Platelet function
effect of smoking on, 31
effect of streptokinase treatment on, 595
POEMS syndrome
presenting with cardiomegaly and cardiomyopathy, 445
Polycythaemia
associated with nocturnal apnoea, 381
Polymyalgia rheumatica
in a married couple, 621
Porphobilinogen deaminase
frequency of low activity in Finland, 389
Post-gastrectomy megaloblastic anaemia
cure of urinary and faecal incontinence in patient with, 313
Post-mortem
decline and fall, 99
Prednimustin
therapy in primary biliary cirrhosis, 139

Primary biliary cirrhosis
prednimustin treatment in, 139
serum hyaluronan and aminoterminal propeptide in, 485
Prognosis
following stroke, 43
in multiple myeloma, 129, 133
in glomerulonephritis, 339
in unstable angina pectoris, 433
Protein
and calcium intake, 181
Protein-loading test
in diagnosis of subclinical diabetic nephropathy, 213
Proteinuria
and cardiovascular risk factors in diabetes, 109
changes during glomerulonephritis, 339
Pseudomonas
infections in AIDS patients, 437

Radioiodine
treatment of recurrent hyperthyroidism, 13
Radionuclide angiocardiography
to assess left ventricular function, 73
Renal anaemia
erythropoietin treatment of, 601
Renal morphology
in diagnosis of subclinical diabetic nephropathy, 213
Rheumatoid arthritis
elevated serum transcobalamin levels in, 547
correction of factor VIII deficiency in, 617

Sauna
and the heart, 319
Sleep apnoea
secondary polycythaemia associated with, 381
Smoking
effects on platelet function, 31
and calcium intake, 181
and diet, 349
coronary heart disease, cancer and mortality, 357
ischaemic heart disease and social class, 477
Social class
ischaemic heart disease and smoking, 477
Sodium restriction
response of atrial natriuretic factor to, 521
Streptokinase
effect on platelet function in myocardial infarction, 595
Stroke
mortality and recurrences following, 43
following myocardial infarction in diabetics, 287
in infective endocarditis, 543
Systemic lupus erythematosus
and related systemic diseases, 67
Systolic function
effect of atenolol vs. hydrochlorothiazide and amiloride, 493

Thyroidectomy
in treatment of Graves' disease, 13
Transcobalamin
levels in anaemia of rheumatoid arthritis, 547
Triglycerides
and insulin resistance, 25
effect of reduction with gemfibrozil, 421
Tumour necrosis factor
in anaemia of rheumatoid arthritis, 547

Twins
systemic rheumatic diseases among, 67
Type III procollagen
aminoterminal propeptide of, 485

Unemployment
and blood pressure, 241
Uraemia
erythrocyte deformability in, 601
Urinary albumin excretion
in diagnosis of subclinical diabetic nephropathy, 213
Urinary incontinence
intravenous vitamin B_{12} therapy for, 313

Vegetations
aspirin to prevent growth of, 543
Vitamin D
and calcium intake, 181
effect in mild primary hyperparathyroidism, 427

Yersinia enterocolitica
associated with liver disease, 531
associated with acute and chronic pancreatitis, 537

Zidovudine
haematopoietic toxicity associated with, 219
hepatitis induced by, 317
Zinc
role in AIDS, 463